View Filing Data

Financial Instruments Disclosure [Text Block]

(3)

Short-Term Financial Instruments

Financial Assets (in millions)

	As of June 30,
	2014		2013

Financial assets:
Cash and cash equivalents	$	81.7	$	66.8
Accounts receivable		18.7		11.0
Total financial assets		100.4		77.8

Financial liabilities:
Accounts payable and current accrued liabilities		26.0		15.8
Total current financial liabilities		26.0		15.8

Net financial assets	$	74.4	$	62.0

The carrying value of the cash and cash equivalents, accounts receivable and accounts payable approximates fair value because of their short-term nature. The Company regularly reviews all financial assets for impairment. There were no impairments recognized in 2014 and 2013.

Note 4 - Fair Value Measurements

12 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value Disclosures [Text Block]

(4)	Fair Value Measurements

A fair value hierarchy has been established which requires the Company to maximize the use of observable inputs, where available, and minimize the use of unobservable inputs when measuring fair value. The fair value hierarchy describes three levels of inputs that may be used to measure fair value:

	Level 1	Quoted prices in active markets for identical assets or liabilities.
	Level 2	Observable inputs other than Level 1 prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.
	Level 3	Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

The following table sets forth the financial assets and liabilities that were measured at fair value on a recurring basis at June 30, 2014, by level within the fair value hierarchy. The assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement.

The Company’s long-term investments have been classified as Level 2, which have been initially valued at the transaction price and subsequently revalued, at the end of each reporting period, utilizing a third party pricing service. The pricing service utilizes industry standard valuation models and observable market inputs to determine value that include surveying the bond dealer community, obtaining benchmark quotes, incorporating relevant trade data, and updating spreads daily. There have been no transfers of assets or liabilities between the fair value measurement classifications.

			Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable
June 30, 2014	Total		(Level 1)		(Level 2)		Inputs (Level 3)

Cash equivalents	$	36.9	$	36.9	$	—	$	—
Long-term investments available-for-sale		10.0		—		10.0		—

Total	$	46.9	$	36.9	$	10.0	$	—

Cash equivalents consist primarily of money market funds. Long-term investments consist of U.S. agency securities and U.S. Treasury securities, classified as available-for-sale and have maturities greater than 365 days from the date of acquisition.

The Company has had no realized gains or losses from the sale of investments for the twelve months ended June 30, 2014. The following table shows the unrealized gains and losses and fair values for those investments as of June 30, 2014 and June 30, 2013 aggregated by major security type:

			Unrealized		Unrealized
June 30, 2014	At Cost		Gains		(Losses)		At Fair Value

Money market funds	$	36.9	$	—	$	—	$	36.9
Debt securities of U.S. government agencies		4.9		—		—		4.9
US Treasury securities		5.1		—		—		5.1
Total	$	46.9	$	—	$	—	$	46.9

Unrealized

June 30, 2013

At Cost

Gains

(Losses)

At Fair Value

Money market funds

—

Debt securities of U.S. government agencies

—

US Treasury securities

—

Total

—

As of June 30, 2014, the Company had investments in an unrealized loss position. The Company has determined that the unrealized losses below $0.1 milllion on these investments at June 30, 2014 are temporary in nature and expects the security to mature at its stated maturity principal. All available-for-sale securities held at June 30, 2014 will mature in over one year.

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

Property, Plant and Equipment [Abstract]

Note 5 - Property and Equipment

12 Months Ended

Jun. 30, 2014

Property, Plant and Equipment Disclosure [Text Block]

(5)	Property and Equipment

Property and equipment consist of the following (in millions):

	As of June 30,
	2014			2013

Property and equipment	$	20.8		$	20.6
Leasehold improvements		6.9			6.8

Total Property and equipment		27.7			27.4
Accumulated depreciation		(25.7	)		(23.1	)

Property and equipment, net	$	2.0		$	4.3

Depreciation and amortization expense was $2.4 million, $3.0 million and $3.1 million for the fiscal years ended June 30, 2014, 2013 and 2012, respectively.

Note 6 - Accrued and Other Current Liabilities

12 Months Ended

Jun. 30, 2014

Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]

(6)

Accrued and Other Current Liabilities

Accrued and other current liabilities consist of the following (in millions):

	As of June 30,
	2014		2013

Professional Fees	$	1.0	$	0.4
Salary and related costs		0.4		2.1
Research and development materials and services		0.8		1.1
Other accrued expenses		1.2		0.3
Total accrued expenses and other liabilities	$	3.4	$	3.9

Note 7 - Public Offering

12 Months Ended

Jun. 30, 2014

Public Offering Disclosure [Text Block] [Abstract]

Public Offering Disclosure [Text Block]

(7)

Public Offering

Public Offering. In January 2014, the Company closed a public offering in which it sold approximately 6.7 million shares of its common stock at a purchase price of $4.30 per share. The net proceeds to the Company from the sale of these shares after underwriting discounts, commissions and other offering expenses were approximately $26.8 million.

Note 8 - Commitments and Contingent Liabilities

12 Months Ended

Jun. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies Disclosure [Text Block]

(8) Commitments and Contingent Liabilities

Operating Leases

The Company has two main operating leases. The lease at 2500 Northwinds Parkway is for the Company’s corporate headquarters in Alpharetta, Georgia. The lease commenced in April, 2013 and expires in September, 2018. The lease includes an escalating base rent schedule as well as a seven month rent holiday and a tenant incentive towards leasehold improvements of approximately $0.1 million which are being recognized as a reduction in rent expense on a straight line basis over the term of the lease. The lease at 585 Blackburn Road, Notting Hill, Victoria, Australia was renewed on September 1, 2014 for one year and expires on September 1, 2015.

Future minimum lease payments, in millions, under non-cancellable operating leases (with initial or remaining lease terms in excess of one year) as of June 30, 2014 are:

2015	$	0.6
2016		0.2
2017		0.2
2018		0.1
2019		0.1
Thereafter		0.0

Total minimum lease payments	$	1.2

Rent expense was $0.7 million, $1.1 million and $0.8 million for the fiscal years ended June 30, 2014, 2013 and 2012, respectively. The Company also has operating lease agreements for office copier equipment under standard terms which are included in the minimum lease payment schedule above.

Note 9 - Income Taxes

12 Months Ended

Jun. 30, 2014

Income Tax Disclosure [Abstract]

Income Tax Disclosure [Text Block]

(9)

Income Taxes

For financial reporting purposes, income before taxes includes the following components:

	Years Ended June 30,
	2014			2013			2012

United States	$	(8.3	)	$	6.5		$	-
Foreign		(3.0	)		(15.3	)		(19.7	)
Total	$	(11.3	)	$	(8.8	)	$	(19.7	)

The expense (benefit) for income taxes is comprised of:

	Years Ended June 30,
	2014			2013		2012
Current:
Federal	$	-		$	-	$	-
State		-			-		-
Foreign		(0.3	)		0.1		(0.3	)
		(0.3	)		0.1		(0.3	)
Deferred:
Federal		-			-		-
State		-			-		-
Foreign		-			-		(0.2	)
		-			-		(0.2	)
Total Tax Expense	$	(0.3	)	$	0.1	$	(0.5	)

The reconciliation between the company's effective tax rate and the statutory rate is as follows:

	Years Ended June 30,
	2014			2013			2012
Income tax expense (benefit) at federal statutory rate	$	(4.0	)	$	(3.3	)	$	(6.9	)
State and local income taxes, net of federal benefit		(0.3	)		0.3			-
Foreign tax rate differential		0.4			1.3			0.9
Change in valuation allowance		4.1			4.2			2.8
Gain on merger		0.1			(3.0	)		-
Research and development expenses		(0.1	)		1.1			2.9
Research and development tax credits		(0.3	)		(1.1	)		(0.3	)
Employee stock options		-			0.5			0.2
Other		(0.2	)		0.1			(0.1	)
Income tax expense (benefit)	$	(0.3	)	$	0.1		$	(0.5	)

The following table includes deferred tax assets and liabilities as of June 30, 2014 and 2013:

	As of June 30,
	2014			2013

Deferred tax assets:
Foreign net operating loss carryforwards	$	18.2		$	18.2
US federal and state loss carryforwards		2.8			-
Amortization		0.8			0.8
Depreciation		0.6			0.2
Accrued compensated-related costs		0.8			0.4
Other		4.3			3.7
Subtotal		27.5			23.3
Less Valuation Allowance		(26.4	)		(21.4	)
Total Net DTA		1.1			1.9

Unearned Income		(1.1	)		(1.9	)

Net deferred tax assets	$	-		$	-

Current net DTL		(0.9	)		(1.5	)
Noncurrent net DTA		0.9			1.5
Net deferred taxes	$	-		$	-

Significant components of deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting and tax purposes. As of June 30, 2014 a full valuation allowance has been established, as the Company has determined that the realization of its deferred tax assets is not more likely than not. The Company recorded $26.4 million and $21.4 million of valuation allowance as of June 30, 2014 and 2013, respectively.

As of June 30, 2014, the Company has had $7.3 million of gross U.S. federal net operating loss carryforwards that expire at various dates through 2034. Under IRC section 382, certain significant changes in ownership may restrict the future utilization of our U.S. tax loss carryforwards. As of June 30, 2014, the Company also has accumulated Australian tax losses of $42.7 million and accumulated United Kingdom tax losses of $26.7 million available for carry forward against future earnings, which under relevant tax laws do not expire but may not be available under certain circumstances.

As of June 30, 2014, the Company’s foreign subsidiaries have no positive accumulated earnings. As such, no federal or state income taxes have been provided on the losses of its foreign subsidiaries under ASC 740. If in the future there are positive earnings generated from the Company’s foreign subsidiaries, the Company will evaluate whether to record any applicable federal and state income taxes on such earnings.

Uncertain Tax Positions

The Company files income tax returns in the U.S, Australia, and the United Kingdom, as well as with various U.S. states. The Company is subject to tax audits in all jurisdictions for which we file income tax returns. Tax audits by their very nature are often complex and can require several years to complete. There are currently no tax audits that have commenced with respect to income tax returns in any jurisdiction.

Under the tax statute of limitations applicable to the Internal Revenue Code, we are no longer subject to U.S. federal income tax examinations by the Internal Revenue Service for years before 2011. Under the statute of limitations applicable to most state income tax laws, the Company is no longer subject to state income tax examinations by tax authorities for years before 2010 in states in which we have filed income tax returns. Certain states may take the position that the Company is subject to income tax in such states even though the Company has not filed income tax returns in such states and, depending on the varying state income tax statutes and administrative practices, the statute of limitations in such states may extend to years before 2009. The Company began foreign operations in 1985. The Company is subject to foreign tax examinations by tax authorities for all years of operations.

The Company does not have any unrecognized tax benefits as of June 30, 2014.

Note 10 - Share-based Compensation

12 Months Ended

Jun. 30, 2014

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Disclosure of Compensation Related Costs, Share-based Payments [Text Block]

(10)

Share-Based Compensation

For the twelve months ended June 30, 2014 and 2013, the Company recorded share-based compensation expense related to grants from equity incentive plans of $1.7 million and $2.6 million, respectively. No income tax benefit was recognized in the statements of operations and no share-based compensation expense was capitalized as part of any assets for the twelve months ended June 30, 2014 and 2013.

Stock Options. The fair value of each stock option award was estimated at its respective date of grant using the Black-Scholes method with the following assumptions:

	Twelve Months Ended
	2014			2013
Weighted-average risk-free interest rate		1.5	%		1.50	%
Dividend yield		—			—
Expected weighted-average volatility		.79			.79
Expected weighted-average term of options (years)		5.92			6.0
Weighted-average fair value of options granted	$	2.47		$	2.39

The risk-free rate interest rate is based on the expected life of the option and the corresponding United States (“U.S.”) Treasury bond, which in most cases is the U.S. five year Treasury bond. The expected term of stock options granted is derived from actual and expected option behavior and represents the period of time that options granted are expected to be outstanding. The Company uses historical data to estimate option exercise patterns and future employee terminations to determine expected life and forfeitures. Expected volatility is based on the historical volatility of the Company’s publicly traded common stock.

	Number of Stock Options			Weighted Average Exercise Price Per Option		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value ($0000)

Balance at June 30, 2013		1,658,529		$	13.57
Granted (1)		912,975			3.95
Exercised		—			—
Forfeited or expired		(108,135	)		34.36
Balance at June 30, 2014		2,463,369		$	9.09		6.34	$	-

(1) Includes performance-based options of 432,975, subject to specific performance conditions.

The Company granted performance-based stock options to purchase 432,975 during the year ending June 30, 2014 with an average exercise price of $4.15, resulting in total unrecognized share-based compensation expense of $1.0 million. Vesting is contingent upon meeting specific performance goals related to the development of laninamivir octanoate. As of June 30, 2014, no share-based compensation expense related to these performance-based options has been recognized as it is not probable that the performance condition will be achieved. The Company will evaluate the probability of achieving these performance goals quarterly, and if the Company determines that it is probable that a performance goal will occur, the effect of the change in estimate will be accounted in the period of change by recording a cumulative catch-up adjustment to retroactively apply the new estimate. As of June 30, 2014, all performance-based options are unvested and will expire six-years from the grant date, or will be forfeited if the performance goals are not achieved.

The total intrinsic value of stock options exercised during the twelve month period ended June 30, 2014 was zero, and no cash proceeds were received by the Company. Further, no actual tax benefits were realized, as the Company currently records a full valuation allowance for all tax benefits due to uncertainties with respect to its ability to generate sufficient taxable income in the future.

The following tables summarize information relating to outstanding and exercisable options as of June 30, 2014:

			June 30, 2014
			Outstanding
					Weighted Average				Exercisable
			Number of		Remaining		Weighted Average		Number of		Weighted Average
Exercise Prices			Shares		Contractual Life		Exercise Price		Shares		Exercise Price
					(In Years)

$2.56	—	$4.05		490,000		9.22	$	3.38		86,250	$	3.96
$4.07				931,590		8.37		4.07		310,531		4.07
$4.13	—	$6.65		628,675		3.49		4.38		—		—
$11.22	—	$93.36		413,104		2.69		34.37		413,104		34.37
				2,463,369		6.34	$	9.09		809,885		19.51

Restricted Stock Awards. A summary of the Company’s outstanding restricted stock activity for the twelve months ended June 30, 2014 is as follows:

				Weighted-Average
				Grant Date
	Shares			Fair Value

Outstanding at June 30, 2013		—		$	—
Granted		54,000			4.10
Released		(45,250	)		4.13
Forfeited		—			—
Outstanding at June 30, 2014		8,750		$	3.93

Restricted and Market Stock Units (MSUs). A summary of the Company’s outstanding restricted stock and market stock unit (MSU) activity for the twelve months ended June 30, 2014 is as follows:

	Shares			Weighted Average Grant Date Fair Value
Outstanding at June 30, 2013		170,139		$	4.07
Awarded		123,183		$	3.86
Released		(17,400	)	$	4.05
Forfeited		(13,850	)	$	4.02
Unvested at June 30, 2014		262,072		$	3.98

In December 2013, the Company awarded 108,183 MSUs to employees that vest on January 1, 2017. The vesting of these awards is subject to the respective employee’s continued employment through this settlement period. The number of MSUs granted represents the target number of units that are eligible to be earned based on the attainment of certain market-based criteria involving our stock price. The number of MSUs actually earned is calculated upon the vesting of the award. Participants may ultimately earn between 0% and 250% of the target number of units granted based on actual stock performance. Accordingly, additional MSUs may be issued or currently outstanding MSUs may be cancelled upon final determination of the number of awards earned. Compensation expense, including the effect of forfeitures, is recognized over the applicable service period.

The Company values grants of MSUs using a lattice model with a Monte Carlo simulation. This valuation methodology utilizes several key assumptions, including the 20-day average closing stock price on the grant date, expected volatility of the Company’s stock price, risk-free rates of return and expected dividend yield. The assumptions used in the Company’s valuation of the MSU’s are summarized as follows:

	For the Twelve Month Period Ended June 30,
	2014		2013
Expected dividend yield		0.00%		—
Expected stock price volatility		0.86		—
Risk-free interest rate		0.64%		—
20-day trading average stock price on grant date		$3.98		—
Weighted-average per share grant date fair value		$7.69		—

As of June 30, 2014 there was $3.5 million of unrecognized share-based compensation expense related to all unvested share-based awards, not discounted for future forfeitures. This balance is expected to be recognized over a weighted-average period of two years.

In August 2014, the Company's Board made a determination that the specific milestone was not and would not be achieved on 432,975 of performance-based stock options, therefore the options will not vest and are cancelled.

Note 11 - Retirement Benefits

12 Months Ended

Jun. 30, 2014

Compensation and Retirement Disclosure [Abstract]

Pension and Other Postretirement Benefits Disclosure [Text Block]

(11)

Retirement Benefits

The Company contributed $0.8 million, $1.1 million and $1.1 million for the fiscal years ended June 30, 2014, 2013 and 2012, respectively, toward standard defined contribution plans for employees. Contributions by the Company for non-U.S. employees can be up to nine per cent of employee salary during fiscal year ending June 30, 2014 and up to four per cent of employee salary for U.S. employees.

Note 12 - Net Loss per Share

12 Months Ended

Jun. 30, 2014

Earnings Per Share [Abstract]

Earnings Per Share [Text Block]

(12)

Net Loss per Share

Basic and diluted loss per share has been computed based on net loss and the weighted-average number of common shares outstanding during the applicable period. For diluted net loss per share, common stock equivalents (shares of common stock issuable upon the exercise of stock options and warrants) are excluded from the calculation of diluted net loss per share as their inclusion would be anti-dilutive. The Company has excluded all options to purchase common stock in periods indicating a loss, as their effect is anti-dilutive.

The following table sets forth the computation of historical basic and diluted net loss per share.

	Year Ended June 30,
	2014			2013			2012

Net loss (in millions)	$	(11.0	)	$	(8.9	)	$	(19.2	)
Weighted average shares outstanding		31,347,888			28,217,515			181,775,444
Weighted average shares outstanding adjusted using exchange ratio used to compute basic earnings per share		-			-			22,713,566
Shares used to compute diluted earnings per share		31,347,888			28,217,515			22,713,566
Basic loss per share	$	(0.35	)	$	(0.32	)	$	(0.85	)
Diluted loss per share	$	(0.35	)	$	(0.32	)	$	(0.85	)
Number of antidilutive stock options excluded from computation		2,725,441			1,828,668			-

Note 13 - Research and Development Credit

12 Months Ended

Jun. 30, 2014

Research and Development [Abstract]

Research, Development, and Computer Software Disclosure [Text Block]

(13) Research and Development Credit

In 2013, an application for a claim of $4.4 million was made by the Company’s subsidiary, Biota Holdings Limited, under the Australian Government’s Research and Development tax incentive when Biota Holdings Limited submitted its tax return for its fiscal year ended June 30, 2012. This amount was recorded as a contingent asset as of June 30, 2012. On November 7, 2012, Biota Holdings Limited received cash for this claim. Although the credit is administered by the Australian government, it is not linked to the level of taxable income and is effectively a government grant. As such, the Company obtained an immediate benefit and therefore, the entire amount has been recognized within non-operating income in the consolidated statement of operations for the year ending June 30, 2013. For 2014, the Company will not receive a research and development credit as its revenue has exceeded the qualifying revenue threshold.

The entire disclosure for research, development, and computer software activities, including contracts and arrangements to be performed for others and with federal government. Includes costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility and in-process research and development acquired in a business combination consummated during the period.

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Note 14 - Licenses, Royalty Collaborative and Contractual Arrangements

12 Months Ended

Jun. 30, 2014

Collaborative Arrangement Disclosure [Text Block]

(14) Licenses, Royalty Collaborative and Contractual Arrangements

Royalty agreements

The Company entered into a royalty-bearing research and license agreement with GSK in 1990 for the development and commercialization of zanamivir, a neuraminidase inhibitor (“NI”) marketed by GSK as Relenza^® to treat influenza. Under the terms of the agreement, the Company licensed zanamivir to GSK on an exclusive, worldwide basis and is entitled to receive royalty payments of 7% of GSK's annual net sales of Relenza^® in the U.S., Europe, Japan and certain other countries as well as 10% of GSK's annual net sales of Relenza^® in Australia, New Zealand, South Africa and Indonesia. The Relenza^® patent portfolio is scheduled to expire as follows: December 2014 in the U.S., May 2015 in Australia, 2016 in the major countries of the European Union (EU), and July 2019 in Japan. GlaxoSmithKline (GSK) has recently verified that the Company will continue to receive royalties on the net sales of Relenza^® in the U.S. beyond December 2014 to the extent that U.S. Patent Application No. 08/737,141 remains pending. On August 25, 2014, GSK filed an appeal to the United States Patent Trial Appeal Board in relation to this patent application.

The Company also generates royalty revenue from the sale of Inavir^® in Japan, pursuant to a collaboration and license agreement that the Company entered into with Daiichi Sankyo in 2009. In September 2010, laninamivir octanoate was approved for sale by the Japanese Ministry of Health and Welfare for the treatment of influenza in adults and children, which Daiichi Sankyo markets as Inavir^®. Under the agreement, the Company currently receives a 4% royalty on net sales of Inavir^® in Japan and is eligible to earn sales milestone payments. Under the collaboration and license agreement, the Company and Daiichi Sankyo have cross-licensed the world-wide rights to develop and commercialize the related intellectual property, and have agreed to share equally in any royalties, license fees, or milestone or other payments received from any third party licenses outside of Japan. Patents on laninamivir octanoate in Japan generally expire in 2024.

Collaborative and contract arrangements

In March 2011, the Company’s wholly owned subsidiary, Biota Scientific Management Pty Ltd., was awarded a contract by BARDA for the late-stage development of laninamivir octanoate on a cost-plus-fixed-fee basis, the total of which is not to exceed $231.2 million. BARDA is part of the U.S. Office of the Assistant Secretary for Preparedness and Response ("ASPR") within the U.S. Department of Health and Human Services ("HHS"). The BARDA contract was designed to fund and provide the Company with all technical and clinical data and U.S. based manufacturing to support the filing of a U.S. new drug application (“NDA”) with the FDA for laninamivir octanoate. The performance period of the BARDA contract commenced on March 31, 2011, and was intended to continue for five years. On May 7, 2014 HHS/ASPR/BARDA notified the Company of its decision to terminate the contract for the development of laninamivir octanoate for the convenience of the U.S. Government. The decision to terminate for convenience was the result of a recently concluded In-Process Review (“IPR”). The Company has been and continues to work with ASPR/BARDA to close out this contract, which involves completing several clinical trials, finalizing separate invoices and billings for those activities undertaken prior to and after the termination date, determining the nature and extent of any equitable adjustments for costs incurred after the termination date, and negotiating a final termination settlement. As of June 30, 2014, the Company had $17.8 million in accounts receivable due from BARDA, which does not include $3.7 million of contract service revenue and accounts receivable that the Company did not recognize for certain expenses that it has incurred in association with the development of LANI and for other equitable adjustments that the Company believes it is entitled to receive under its terminated contract with BARDA and pursuant to applicable government regulations, but for which it potentially may not be fully reimbursed.

The Company is considered an active participant in the BARDA contract, with exposure to significant risks and rewards of commercialization relating to the development of laninamivir octanoate. Therefore, revenues from and costs associated with the contract are recorded and recognized on a gross basis in the consolidated statement of operations.

The following tables summarize the key components of the Company’s revenues (in millions):

	Years Ended June 30,
	2014		2013		2012
Royalty revenue – Relenza^®	$	10.6	$	2.6	$	4.4
– Inavir^®		4.5		4.2		4.5
Commercial milestone – Inavir^®		-		2.8		-
Revenue from services		53.6		24.0		11.5
Total revenue	$	68.7	$	33.6	$	20.4

Note 15 - Restructuring Charges

12 Months Ended

Jun. 30, 2014

Restructuring and Related Activities [Abstract]

Restructuring and Related Activities Disclosure [Text Block]

(15) Restructuring Charges

We recognize restructuring charges when a plan that materially changes the scope of our business or the manner in which that business is conducted is adopted and communicated to the impacted parties, and the expenses have been incurred or are reasonably estimable.

Fiscal 2014 Restructuring Activity

In the fourth quarter of fiscal 2014, we announced restructuring actions as a result of the termination for convenience of the BARDA contract. These restructuring activities are expected to be completed in fiscal 2015. We recorded $2.1 million in restructuring charges during fiscal 2014, which comprised of severance and other employee related benefits. $0.9 million was recorded in cost of revenue, $1.0 million in research and development and $0.2 million in general and administrative. As of June 30, 2014, we had a remaining liability of approximately $2.0 million.

Following is a reconciliation of the beginning and ending balances of the restructuring liability:

	Balance at							Balance at
	June 30,							June 30,
Fiscal 2014 Restructuring Plans:	2013		Provision		Payments			2014
Severance and employment costs		—		2.1		(0.1	)	$	2.0
Total restructuring costs	$	—	$	2.1	$	(0.1	)	$	2.0

The remaining severance and other employment costs of approximately $2.0 million will be paid in fiscal 2015. Also, included in accrued severance are balances of $1.2 million and $1.0 million as of June 30, 2014 and 2013, respectively. These balances relate to acquired severance balances as part of the Nabi merger. This remaining balance is to be paid in fiscal 2015.

Note 16 - Quarterly Financial Information (Unaudited)

12 Months Ended

Jun. 30, 2014

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Information [Text Block]

(16) Quarterly Financial Information (Unaudited)

The table below sets forth summary unaudited consolidated quarterly financial information for the years ended June 30, 2014 and 2013 (in millions):

	Quarter Ended
	6/30/2014			3/31/2014		12/31/2013			9/30/2013
Revenues	$	8.5		$	29.5	$	18.5		$	12.3
Operating expenses	19.0			19.3			11.4			10.7
Net (loss) income		(10.2	)		3.2		(0.1	)		(3.9	)
Net (loss) income per share (1):
Basic	$	(.29	)	$	0.09	$	0.00		$	(0.14	)
Diluted	$	(.29	)	$	0.09	$	0.00		$	(0.14	)

	Quarter Ended
	6/30/2013			3/31/2013		12/31/2012		9/30/2012
Revenues	$	9.3		$	12.5	$	10.4	$	1.4
Operating expenses		7.7			4.1		7.1		1.5
Net loss		(6.5	)		0.2		4.6		(7.2	)
Net loss per share (1):
Basic	$	(0.23	)	$	0.01	$	0.16	$	(0.32	)
Diluted	$	(0.23	)	$	0.01	$	0.16	$	(0.32	)

)

Due to the use of the weighted average shares outstanding for each quarter for computing earnings per share, the sum of the quarterly per share amounts may not equal the per share amount for the year.

Accounting Policies, by Policy (Policies)	12 Months Ended
Accounting Policies, by Policy (Policies)	Jun. 30, 2014
Accounting Policies [Abstract]
Basis of Accounting, Policy [Policy Text Block]	Basis of Presentation and Principles of Consolidation The accompanying consolidated financial statements of Biota Pharmaceuticals, Inc. and its wholly owned subsidiaries have been prepared in accordance with accounting principles generally accepted in the United States (“GAAP”). All intercompany balances and transactions have been eliminated in consolidation. The Company’s fiscal year ends on June 30. The Company operates as one operating segment.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates The preparation of the consolidated financial statements requires management of the Company to make a number of estimates and assumptions relating to the reported amount of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the period. Significant items subject to such estimates and assumptions include accruals and obligations, tangible and intangible assets and deferred income taxes. Actual results could differ from those estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments Financial instruments include cash and cash equivalents, investments, accounts receivable, accounts payable and accrued liabilities. The carrying amounts of those financial instruments are considered to be representative of their respective fair values because of the short-term nature of those investments.
Cash and Cash Equivalents, Policy [Policy Text Block]	Cash Equivalents and Investments Cash equivalents consist of short-term, highly liquid investments with original maturities of 90 or fewer days when purchased. Investments with original maturities between 90 and 365 days when purchased are considered to be short-term investments. Investments with original maturities over 365 days when purchased are considered to be long-term investments The Company has classified its entire investment portfolio as available-for-sale. These securities are recorded as either cash equivalents, short term or long term investments. Short-term and long-term investments are carried at the fair value based upon observable inputs based on quoted market prices. The amortized cost of securities is adjusted for amortization of premiums and accretion of discounts to maturity. Amortization and accretion are included in interest income, net, and realized gains and losses are also included in interest income, net. All unrealized gains and losses are reported in other comprehensive loss. The cost basis of all securities sold is based on the specific identification method. Available-for-sale securities as of June 30, 2014 consisted primarily of U.S. treasury securities and U.S. government agency securities.
Concentration Risk, Credit Risk, Policy [Policy Text Block]	Concentration of Credit Risk and Other Risks and Uncertainties Cash, cash equivalents and short and long term investments consist of financial instruments that potentially subject the Company to concentrations of credit risk to the extent recorded on the balance sheets. The Company believes that it has established guidelines for investment of its excess cash that maintain principal and liquidity through its policies on concentration, diversification, investment maturity, and investment grade.
Receivables, Policy [Policy Text Block]	Receivables Accounts receivable are recorded at the invoiced amount. An allowance for doubtful accounts is estimated based on probable credit losses in the existing accounts receivable. The allowance is determined based on a review of individual accounts for collectability, generally focusing on those that are past due. The current year expense to adjust the allowance for doubtful accounts, if any, is recorded in the consolidated statement of operations. An allowance for uncollectible accounts receivable is estimated based on a combination of default history, aging analysis and any specific, known troubled accounts. When a receivable is finally established as uncollectible, it is written off against the allowance account for accounts receivables. The allowance for doubtful accounts balance is $0 as of June 30, 2014 and 2013, respectively.
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment Property and equipment are recorded at acquisition cost, net of accumulated depreciation and impairment. Depreciation on property and equipment is calculated using the straight-line method over the estimated useful lives of the assets. The estimated useful life of machinery and equipment is three to 10 years. Leasehold improvements are amortized using the straight-line method over the shorter of the remaining lease term or estimated useful life of the asset. Maintenance and repairs are charged to operations as incurred.
Intangible Assets, Finite-Lived, Policy [Policy Text Block]	Intangible Assets Intangible assets generally consist of two elements: Royalty prepayments. Royalty prepayments represent expenditures made to research institutions where the parties agreed to exchange future variable royalty payments in relation to intellectual property for a fixed payment. These prepayments have a finite useful life, usually being the expiration of the underlying patent or contract, and are carried at the present value of costs at acquisition date, less accumulated amortization. Amortization is based on the anticipated usage of the asset, determined with reference to expected sales of the related product over the contract or patent life. Computer software. Costs incurred in acquiring software and licenses that are expected to provide future period financial benefits are capitalized to computer software. Amortization is calculated on a straight-line basis over periods ranging from one to three years.
Lease, Policy [Policy Text Block]	Leased Assets The Company accounts for its leases at their inception as either an operating or capital lease, depending on certain defined criteria. All of the Company’s leases in effect at June 30, 2014 and June 30, 2013 are considered operating leases. The costs of operating leases are charged to the consolidated statement of operations on a straight-line basis over the lease term. The difference between cash rent payments and straight line rent expense is recorded as deferred rent liability. The balance of deferred rent liabilities is classified in the balance sheet as other liabilities. Additionally, any incentives the Company receives are treated as a reduction of expenses over the term of the agreement. Leasehold improvements by the Company or landlord are capitalized at cost and amortized over the lesser of their expected useful life or the life of the lease, without assuming renewal features, if any, are exercised.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]	Impairment of Long-lived Assets The Company reviews its tangible and intangible assets, including patents and licenses, for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. In performing an impairment review, the Company estimates undiscounted cash flows from products that are covered by these patents and licenses. An impairment loss would be recognized when estimated undiscounted future cash flows expected to result from the use of the asset and its eventual disposition is less than the carrying amount of the asset. If the evaluation indicates that the carrying value of an asset is not recoverable from its undiscounted cash flows, an impairment loss is measured by comparing the carrying value of the asset to its fair value.
Foreign Currency Transactions and Translations Policy [Policy Text Block]	Foreign Currency Functional and reporting currency. Items included in the Company’s consolidated financial statements are measured using the currency of the primary economic environment in which the entity operates, referred to as the functional currency. The Company operates in several jurisdictions with functional currencies of the U.S. dollar, the Australian dollar, and British Pound. The consolidated financial statements are presented in U.S. dollars. Transactions and balances. Foreign currency transactions are translated into the functional currency using the exchange rates prevailing at the dates of the related transactions. Foreign exchange gains and losses resulting from the settlement of such transactions, as well as from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies, are recognized in the consolidated statements of operations. The results and financial position of any operations that have a functional currency different from the U.S. dollar are translated into U.S. dollar amounts. Assets and liabilities are translated into U.S. dollars at exchange rates in effect at the balance sheet date. Income and expense items are translated at average rates for the period. All resulting exchange differences are recognized as accumulated other comprehensive income, a separate component of stockholders’ equity. On consolidation, exchange differences arising from the translation of any net investment in foreign entities are recorded in stockholders’ equity as part of accumulated other comprehensive income, net of related taxes.
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]	Patent and License Expense Legal fees incurred for patents relating to commercialized products are capitalized and amortized over the life of the patents and reported in research and development expense. Legal fees incurred for patent application costs have been charged to expense and reported in research and development expense.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]	Share-Based Compensation Expense Share-based compensation expense relates to stock options, restricted stock units or other equity-based grants. The fair market value of stock options is determined at the grant date using an option pricing model based on the closing price of the Company’s common stock on that date. The fair market value of restricted stock units or other equity-based grants are also determined at the grant date, based on the closing price of the Company’s common stock on that date. The value of the awards that are ultimately expected to vest is recognized, net of forfeitures, as an expense on a straight-line basis over the employee's requisite service period.
Income Tax, Policy [Policy Text Block]	Income Taxes The Company applies ASC 740 – Income Taxes, which established financial accounting and reporting requirements for the effects of income taxes that result from the Company’s activities during the current and preceding years. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and operating losses and tax credit carry forwards. Deferred tax assets and liabilities are measured using enacted statutory tax rates expected to apply to taxable income in the jurisdictions and years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Where the Company determines that it is more likely than not that some portion or all of the deferred tax assets will not be realized in the future, the deferred tax assets are reduced by a valuation allowance. The valuation allowance is sufficient to reduce the deferred tax assets to the amount that the Company determines is more likely than not to be realized.
Revenue Recognition, Policy [Policy Text Block]	Revenue Recognition Revenue consists primarily of royalty payments, license fees, milestone payments, payments for services performed pursuant to contracts and certain research and development activities pursuant to collaborations with other corporate entities. Revenue from royalties is recognized when the net sales of the underlying product by the relevant third party, including actual or estimated returns within the royalty period based on agreement, are determinable. The Company receives estimates of the amount of royalty revenue from its licensees on a quarterly basis, based on the license agreement. Revenue from services performed pursuant to contracts or grants is recognized when earned, typically when the underlying services or activities are rendered. When circumstances arise where collection of the underlying services is uncertain, recognition of the revenue is delayed until such time as collection is reasonably assured. The Company analyzes cost reimbursable grants and contracts to determine whether it should report such reimbursements as revenue, or as an offset to the related research and development expenses incurred. For costs incurred and revenues generated from third parties where the Company is deemed to be the principal participant, such as the BARDA contract, it recognizes revenue and costs using the gross basis of accounting. Revenue for collaborative research and development activities typically consists of fees for services, or payments when specific milestones are met and match underlying activities occurring during the term of the arrangement. For milestones that are deemed substantive, the Company recognizes the contingent revenue when: (i) the milestones have been achieved; (ii) no further performance obligations with respect to the milestones exist; and (iii) collection is reasonably assured. A milestone is considered substantive if all of the following conditions are met: (i) the milestone is non-refundable; (ii) achievement of the milestone was not reasonably assured at the inception of the arrangement; (iii) substantive effort is involved to achieve the milestone; and (iv) the amount of the milestone appears reasonable in relation to the effort expended with the other milestones in the arrangement and the related risk associated with achievement of the milestone. If a milestone is deemed not to be substantive, the Company recognizes the portion of the milestone payment as revenue that correlates to activities already performed; the remaining portion of the milestone payment is deferred and recognized as revenue as the Company completes its performance obligations.
Cost of Sales, Policy [Policy Text Block]	Cost of Revenue Cost of revenue expense includes, but is not limited to, reimbursement for the cost of third-party service providers incurred in connection with conducting external preclinical studies and treating patients enrolled in clinical trials and monitoring, accumulating and evaluating the related clinical data; salaries and personnel-related expenses for internal staff allocated to a contract, including benefits; and the cost to develop, formulate and manufacture product candidates directly allocated to a specific contract. Cost of Revenue expenses are expensed as incurred.
Research and Development Expense, Policy [Policy Text Block]	Research and Development Expense Research and development expense includes, but is not limited to, the costs of activities associated with: drug discovery, such as medicinal chemistry, virology, microbiology, and biochemistry; drug target discovery, molecular biology and structural biology; fees paid to third-party service providers in connection with conducting external preclinical studies and treating patients enrolled in clinical trials and monitoring, accumulating and evaluating the related clinical data; salaries and personnel-related expenses for our internal staff, including benefits and share-based compensation; the cost to develop, formulate and manufacture product candidates; legal fees associated with patents and intellectual property related to our product candidates; research consulting fees; license expenses and sponsored research fees paid to third parties; and specialized information systems, depreciation and laboratory facility costs. Research and development expenses are expensed as incurred.
Selling, General and Administrative Expenses, Policy [Policy Text Block]	General and Administrative Expense General and administrative expense reflects the costs incurred to support our operations and research and development activities. General and administrative expense consists primarily of salaries and personnel-related expenses, including share-based compensation for personnel in executive, finance, accounting, information technology, business development and human resources functions. Other significant costs include professional fees for legal and auditing services, as well as premiums for insurance, other expenses as a result of being a publicly traded company, and depreciation and facility expenses.
Comprehensive Income, Policy [Policy Text Block]	Total Comprehensive Income (loss) Comprehensive income is defined as the total change in stockholders’ equity during the period other than from transactions with stockholders, and for the Company, includes net income (loss) and cumulative translation foreign currency adjustments.
Limited Suppliers Policy [Policy Text Block]	Limited SuppliersThe Company may rely on single-source third-party suppliers and contract manufacturers to formulate or manufacture its product candidates pursuant to FDA current good manufacturing practices (“cGMP”) requirements. The failure of single-source suppliers or single-source contract manufacturers to produce and deliver specific candidates on a timely basis, or at all, could delay or interrupt the development process and affect the Company’s operating results.
Reclassification, Policy [Policy Text Block]	Reclassifications Certain reclassifications have been made to prior period amounts to conform to the current year presentation.
Revisions, Policy [Policy Text Block]	Revision In connection with the analysis of deferred tax balances in 2014, the Company identified an error that required correction to the 2013 financial statements and related footnote disclosure to properly reflect the deferred tax assets and liabilities as of June 30, 2013. Accordingly, certain deferred tax assets and liabilities in the 2013 Balance sheet have been revised. The revision increased non-current deferred tax assets by $1.5 million and increased current deferred tax liabilities by $1.5 million as of June 30, 2013. The revision had no impact on the previously reported net deferred taxes, income tax expense, net loss, Stockholders’ equity, or cash flow."
New Accounting Pronouncements, Policy [Policy Text Block]	Recent Accounting Standards In May 2014, the Financial Accounting Standards Board issued authoritative accounting guidance related to revenue from contracts with customers. This guidance is a comprehensive new revenue recognition model that requires a company to recognize revenue to depict the transfer of goods or services to a customer at an amount that reflects the consideration it expects to receive in exchange for those goods or services. This guidance is effective for annual reporting periods beginning after December 15, 2016 and early adoption is not permitted. The Company will adopt this guidance on July 1, 2017. Companies may use either a full retrospective or a modified retrospective approach to adopt this guidance. The Company is evaluating which transition approach to use and its impact, if any, on its consolidated financial statements.

Note 3 - Short-Term Financial Instruments (Tables)

12 Months Ended

Jun. 30, 2014

Fair Value, by Balance Sheet Grouping [Table Text Block]

	As of June 30,
	2014		2013

Financial assets:
Cash and cash equivalents	$	81.7	$	66.8
Accounts receivable		18.7		11.0
Total financial assets		100.4		77.8

Financial liabilities:
Accounts payable and current accrued liabilities		26.0		15.8
Total current financial liabilities		26.0		15.8

Net financial assets	$	74.4	$	62.0

Note 4 - Fair Value Measurements (Tables)

12 Months Ended

Jun. 30, 2014

Fair Value Disclosures [Abstract]

Fair Value, Assets Measured on Recurring Basis [Table Text Block]

			Quoted Prices in Active Markets for Identical Assets		Significant Other Observable Inputs		Significant Unobservable
June 30, 2014	Total		(Level 1)		(Level 2)		Inputs (Level 3)

Cash equivalents	$	36.9	$	36.9	$	—	$	—
Long-term investments available-for-sale		10.0		—		10.0		—

Total	$	46.9	$	36.9	$	10.0	$	—

Unrealized Gain (Loss) on Investments [Table Text Block]

			Unrealized		Unrealized
June 30, 2014	At Cost		Gains		(Losses)		At Fair Value

Money market funds	$	36.9	$	—	$	—	$	36.9
Debt securities of U.S. government agencies		4.9		—		—		4.9
US Treasury securities		5.1		—		—		5.1
Total	$	46.9	$	—	$	—	$	46.9

Unrealized

June 30, 2013

At Cost

Gains

(Losses)

At Fair Value

Money market funds

—

Debt securities of U.S. government agencies

—

US Treasury securities

—

Total

—

Note 5 - Property and Equipment (Tables)

12 Months Ended

Jun. 30, 2014

Property, Plant and Equipment [Abstract]

Property, Plant and Equipment [Table Text Block]

	As of June 30,
	2014			2013

Property and equipment	$	20.8		$	20.6
Leasehold improvements		6.9			6.8

Total Property and equipment		27.7			27.4
Accumulated depreciation		(25.7	)		(23.1	)

Property and equipment, net	$	2.0		$	4.3

Note 6 - Accrued and Other Current Liabilities (Tables)

12 Months Ended

Jun. 30, 2014

Schedule of Accrued Liabilities [Table Text Block]

	As of June 30,
	2014		2013

Professional Fees	$	1.0	$	0.4
Salary and related costs		0.4		2.1
Research and development materials and services		0.8		1.1
Other accrued expenses		1.2		0.3
Total accrued expenses and other liabilities	$	3.4	$	3.9

Note 8 - Commitments and Contingent Liabilities (Tables)

12 Months Ended

Jun. 30, 2014

Commitments and Contingencies Disclosure [Abstract]

Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]

2015	$	0.6
2016		0.2
2017		0.2
2018		0.1
2019		0.1
Thereafter		0.0

Total minimum lease payments	$	1.2

Note 9 - Income Taxes (Tables)

12 Months Ended

Jun. 30, 2014

Income Tax Disclosure [Abstract]

Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]

	Years Ended June 30,
	2014			2013			2012

United States	$	(8.3	)	$	6.5		$	-
Foreign		(3.0	)		(15.3	)		(19.7	)
Total	$	(11.3	)	$	(8.8	)	$	(19.7	)

Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]

	Years Ended June 30,
	2014			2013		2012
Current:
Federal	$	-		$	-	$	-
State		-			-		-
Foreign		(0.3	)		0.1		(0.3	)
		(0.3	)		0.1		(0.3	)
Deferred:
Federal		-			-		-
State		-			-		-
Foreign		-			-		(0.2	)
		-			-		(0.2	)
Total Tax Expense	$	(0.3	)	$	0.1	$	(0.5	)

Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]

	Years Ended June 30,
	2014			2013			2012
Income tax expense (benefit) at federal statutory rate	$	(4.0	)	$	(3.3	)	$	(6.9	)
State and local income taxes, net of federal benefit		(0.3	)		0.3			-
Foreign tax rate differential		0.4			1.3			0.9
Change in valuation allowance		4.1			4.2			2.8
Gain on merger		0.1			(3.0	)		-
Research and development expenses		(0.1	)		1.1			2.9
Research and development tax credits		(0.3	)		(1.1	)		(0.3	)
Employee stock options		-			0.5			0.2
Other		(0.2	)		0.1			(0.1	)
Income tax expense (benefit)	$	(0.3	)	$	0.1		$	(0.5	)

Schedule of Deferred Tax Assets and Liabilities [Table Text Block]

	As of June 30,
	2014			2013

Deferred tax assets:
Foreign net operating loss carryforwards	$	18.2		$	18.2
US federal and state loss carryforwards		2.8			-
Amortization		0.8			0.8
Depreciation		0.6			0.2
Accrued compensated-related costs		0.8			0.4
Other		4.3			3.7
Subtotal		27.5			23.3
Less Valuation Allowance		(26.4	)		(21.4	)
Total Net DTA		1.1			1.9

Unearned Income		(1.1	)		(1.9	)

Net deferred tax assets	$	-		$	-

Current net DTL		(0.9	)		(1.5	)
Noncurrent net DTA		0.9			1.5
Net deferred taxes	$	-		$	-

Note 10 - Share-based Compensation (Tables)

12 Months Ended

Jun. 30, 2014

MSU [Member]

Note 10 - Share-based Compensation (Tables) [Line Items]

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	For the Twelve Month Period Ended June 30,
	2014		2013
Expected dividend yield		0.00%		—
Expected stock price volatility		0.86		—
Risk-free interest rate		0.64%		—
20-day trading average stock price on grant date		$3.98		—
Weighted-average per share grant date fair value		$7.69		—

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

	Twelve Months Ended
	2014			2013
Weighted-average risk-free interest rate		1.5	%		1.50	%
Dividend yield		—			—
Expected weighted-average volatility		.79			.79
Expected weighted-average term of options (years)		5.92			6.0
Weighted-average fair value of options granted	$	2.47		$	2.39

Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]

	Number of Stock Options			Weighted Average Exercise Price Per Option		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value ($0000)

Balance at June 30, 2013		1,658,529		$	13.57
Granted (1)		912,975			3.95
Exercised		—			—
Forfeited or expired		(108,135	)		34.36
Balance at June 30, 2014		2,463,369		$	9.09		6.34	$	-

Schedule of Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range [Table Text Block]

			June 30, 2014
			Outstanding
					Weighted Average				Exercisable
			Number of		Remaining		Weighted Average		Number of		Weighted Average
Exercise Prices			Shares		Contractual Life		Exercise Price		Shares		Exercise Price
					(In Years)

$2.56	—	$4.05		490,000		9.22	$	3.38		86,250	$	3.96
$4.07				931,590		8.37		4.07		310,531		4.07
$4.13	—	$6.65		628,675		3.49		4.38		—		—
$11.22	—	$93.36		413,104		2.69		34.37		413,104		34.37
				2,463,369		6.34	$	9.09		809,885		19.51

Nonvested Restricted Stock Shares Activity [Table Text Block]

				Weighted-Average
				Grant Date
	Shares			Fair Value

Outstanding at June 30, 2013		—		$	—
Granted		54,000			4.10
Released		(45,250	)		4.13
Forfeited		—			—
Outstanding at June 30, 2014		8,750		$	3.93

Schedule of Nonvested Performance-based Units Activity [Table Text Block]

	Shares			Weighted Average Grant Date Fair Value
Outstanding at June 30, 2013		170,139		$	4.07
Awarded		123,183		$	3.86
Released		(17,400	)	$	4.05
Forfeited		(13,850	)	$	4.02
Unvested at June 30, 2014		262,072		$	3.98

Note 12 - Net Loss per Share (Tables)

12 Months Ended

Jun. 30, 2014

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

	Year Ended June 30,
	2014			2013			2012

Net loss (in millions)	$	(11.0	)	$	(8.9	)	$	(19.2	)
Weighted average shares outstanding		31,347,888			28,217,515			181,775,444
Weighted average shares outstanding adjusted using exchange ratio used to compute basic earnings per share		-			-			22,713,566
Shares used to compute diluted earnings per share		31,347,888			28,217,515			22,713,566
Basic loss per share	$	(0.35	)	$	(0.32	)	$	(0.85	)
Diluted loss per share	$	(0.35	)	$	(0.32	)	$	(0.85	)
Number of antidilutive stock options excluded from computation		2,725,441			1,828,668			-

Note 14 - Licenses, Royalty Collaborative and Contractual Arrangements (Tables)

12 Months Ended

Jun. 30, 2014

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

	Years Ended June 30,
	2014		2013		2012
Royalty revenue – Relenza^®	$	10.6	$	2.6	$	4.4
– Inavir^®		4.5		4.2		4.5
Commercial milestone – Inavir^®		-		2.8		-
Revenue from services		53.6		24.0		11.5
Total revenue	$	68.7	$	33.6	$	20.4

Note 15 - Restructuring Charges (Tables)

12 Months Ended

Jun. 30, 2014

Restructuring and Related Activities [Abstract]

Restructuring and Related Costs [Table Text Block]

	Balance at							Balance at
	June 30,							June 30,
Fiscal 2014 Restructuring Plans:	2013		Provision		Payments			2014
Severance and employment costs		—		2.1		(0.1	)	$	2.0
Total restructuring costs	$	—	$	2.1	$	(0.1	)	$	2.0

Note 16 - Quarterly Financial Information (Unaudited) (Tables)

12 Months Ended

Jun. 30, 2014

Quarterly Financial Information Disclosure [Abstract]

Schedule of Quarterly Financial Information [Table Text Block]

	Quarter Ended
	6/30/2014			3/31/2014		12/31/2013			9/30/2013
Revenues	$	8.5		$	29.5	$	18.5		$	12.3
Operating expenses	19.0			19.3			11.4			10.7
Net (loss) income		(10.2	)		3.2		(0.1	)		(3.9	)
Net (loss) income per share (1):
Basic	$	(.29	)	$	0.09	$	0.00		$	(0.14	)
Diluted	$	(.29	)	$	0.09	$	0.00		$	(0.14	)

	Quarter Ended
	6/30/2013			3/31/2013		12/31/2012		9/30/2012
Revenues	$	9.3		$	12.5	$	10.4	$	1.4
Operating expenses		7.7			4.1		7.1		1.5
Net loss		(6.5	)		0.2		4.6		(7.2	)
Net loss per share (1):
Basic	$	(0.23	)	$	0.01	$	0.16	$	(0.32	)
Diluted	$	(0.23	)	$	0.01	$	0.16	$	(0.32	)

Note 1 - Company Overview (Details) $ in Millions	12 Months Ended
Note 1 - Company Overview (Details) $ in Millions	Jun. 30, 2014 USD ($)
BARDA
Note 1 - Company Overview (Details) [Line Items]
Contracts Revenue	$ 231

Note 2 - Summary of Significant Accounting Policies (Details)	12 Months Ended
	Jun. 30, 2014 USD ($)	Jun. 30, 2013 USD ($)
Non-Current Deferred Tax Assets [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Quantifying Misstatement in Current Year Financial Statements, Amount	$ 1,500,000
Current Deferred Tax Liabilities [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Quantifying Misstatement in Current Year Financial Statements, Amount	$ (1,500,000)
Computer Software, Intangible Asset [Member] \| Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	1 year
Computer Software, Intangible Asset [Member] \| Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Finite-Lived Intangible Asset, Useful Life	3 years
Minimum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	3 years
Maximum [Member]
Note 2 - Summary of Significant Accounting Policies (Details) [Line Items]
Property, Plant and Equipment, Useful Life	10 years
Number of Operating Segments	1
Allowance for Doubtful Accounts Receivable	$ 0	$ 0

Note 3 - Short-Term Financial Instruments (Details) - Financial Assets - USD ($) $ in Millions	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012	Jun. 30, 2011
Financial assets:
Cash and cash equivalents	$ 81.7	$ 66.8	$ 53.8	$ 74.2
Accounts receivable	18.7	11.0
Total financial assets	100.4	77.8
Financial liabilities:
Accounts payable and current accrued liabilities	26.0	15.8
Total current financial liabilities	26.0	15.8
Net financial assets	$ 74.4	$ 62.0

Note 4 - Fair Value Measurements (Details)	12 Months Ended
Note 4 - Fair Value Measurements (Details)	Jun. 30, 2014 USD ($)
Fair Value Disclosures [Abstract]
Gain (Loss) on Sale of Investments	$ 0
Maximum Unrealized Loss Positions Maturing In Excess Of One Year	$ 0.1

Note 4 - Fair Value Measurements (Details) - Summary of Investments $ in Millions	Jun. 30, 2014 USD ($)
Fair Value, Inputs, Level 1 [Member] \| Money Market Funds [Member]
Note 4 - Fair Value Measurements (Details) - Summary of Investments [Line Items]
Cash equivalents	$ 36.9
Fair Value, Inputs, Level 1 [Member]
Note 4 - Fair Value Measurements (Details) - Summary of Investments [Line Items]
Total	36.9
Fair Value, Inputs, Level 2 [Member]
Note 4 - Fair Value Measurements (Details) - Summary of Investments [Line Items]
Long-term investments available-for-sale	10.0
Total	10.0
Money Market Funds [Member]
Note 4 - Fair Value Measurements (Details) - Summary of Investments [Line Items]
Cash equivalents	36.9
Long-term investments available-for-sale	10.0
Total	$ 46.9

Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.

Performance Shares [Member] | Subsequent Event [Member]

Note 4 - Fair Value Measurements (Details) - Summary of Unrealized Gains and Losses on Investments $ in Millions	Jun. 30, 2014 USD ($)
US Government Agencies Debt Securities [Member]
Note 4 - Fair Value Measurements (Details) - Summary of Unrealized Gains and Losses on Investments [Line Items]
At Cost	$ 4.9
At Fair Value	4.9
US Treasury Securities [Member]
Note 4 - Fair Value Measurements (Details) - Summary of Unrealized Gains and Losses on Investments [Line Items]
At Cost	5.1
At Fair Value	5.1
Money Market Funds [Member]
Note 4 - Fair Value Measurements (Details) - Summary of Unrealized Gains and Losses on Investments [Line Items]
At Cost	36.9
At Fair Value	36.9
At Fair Value	10.0
At Cost	46.9
At Fair Value	$ 46.9

Note 5 - Property and Equipment (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Property, Plant and Equipment [Abstract]
Depreciation, Depletion and Amortization	$ 2.4	$ 3.0	$ 3.1

Note 5 - Property and Equipment (Details) - Property and Equipment - USD ($) $ in Millions	Jun. 30, 2014	Jun. 30, 2013
Property and Equipment [Abstract]
Property and equipment	$ 20.8	$ 20.6
Leasehold improvements	6.9	6.8
Total Property and equipment	27.7	27.4
Accumulated depreciation	(25.7)	(23.1)
Property and equipment, net	$ 2.0	$ 4.3

Note 6 - Accrued and Other Current Liabilities (Details) - Accrued and Other Current Liabilities - USD ($) $ in Millions	Jun. 30, 2014	Jun. 30, 2013
Accrued and Other Current Liabilities [Abstract]
Professional Fees	$ 1.0	$ 0.4
Salary and related costs	0.4	2.1
Research and development materials and services	0.8	1.1
Other accrued expenses	1.2	0.3
Total accrued expenses and other liabilities	$ 3.4	$ 3.9

Note 7 - Public Offering (Details) - USD ($) $ / shares in Units, shares in Millions, $ in Millions	1 Months Ended	12 Months Ended
	Jan. 31, 2014	Jun. 30, 2014
Public Offering [Member]
Note 7 - Public Offering (Details) [Line Items]
Stock Issued During Period, Shares, New Issues	6.7
Sale of Stock, Price Per Share	$ 4.30
Proceeds from Issuance of Common Stock	$ 26.8
Proceeds from Issuance of Common Stock		$ 26.8

Note 8 - Commitments and Contingent Liabilities (Details) - USD ($) $ in Millions		12 Months Ended
	Sep. 01, 2014	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Subsequent Event [Member] \| Lease at 585 Blackburn Road, Notting Hill, Victoria, Australia [Member]
Note 8 - Commitments and Contingent Liabilities (Details) [Line Items]
Lessee Leasing Arrangements, Operating Leases, Renewal Term	1 year
Lease at 2500 Northwinds Parkway, Alpharetta, Georgia [Member]
Note 8 - Commitments and Contingent Liabilities (Details) [Line Items]
Leasehold Improvements, Gross		$ 0.1
Leasehold Improvements, Gross		6.9	$ 6.8
Operating Leases, Rent Expense		$ 0.7	$ 1.1	$ 0.8

Note 8 - Commitments and Contingent Liabilities (Details) - Future Minimum Lease Payments $ in Millions	Jun. 30, 2014 USD ($)
Future Minimum Lease Payments [Abstract]
2015	$ 0.6
2016	0.2
2017	0.2
2018	0.1
2019	0.1
Thereafter	0.0
Total minimum lease payments	$ 1.2

Note 9 - Income Taxes (Details) - USD ($) $ in Millions	Jun. 30, 2014	Jun. 30, 2013
Australian Taxation Office [Member]
Note 9 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	$ 42.7
Her Majesty's Revenue and Customs (HMRC) [Member]
Note 9 - Income Taxes (Details) [Line Items]
Operating Loss Carryforwards	26.7
Deferred Tax Assets, Valuation Allowance	26.4	$ 21.4
Operating Loss Carryforwards	$ 7.3

Note 9 - Income Taxes (Details) - Summary of Income Before Taxes, Domestic and Foreign - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Summary of Income Before Taxes, Domestic and Foreign [Abstract]
United States	$ (8.3)	$ 6.5
Foreign	(3.0)	(15.3)	$ (19.7)
Total	$ (11.3)	$ (8.8)	$ (19.7)

Note 9 - Income Taxes (Details) - Components of Income Tax Expense (Benefit) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Current:
Foreign	$ (0.3)	$ 0.1	$ (0.3)
	(0.3)	0.1	(0.3)
Deferred:
Foreign			(0.2)
			(0.2)
Total Tax Expense	$ (0.3)	$ 0.1	$ (0.5)

Note 9 - Income Taxes (Details) - Reconciliation of Effective Tax Rate - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Reconciliation of Effective Tax Rate [Abstract]
Income tax expense (benefit) at federal statutory rate	$ (4.0)	$ (3.3)	$ (6.9)
State and local income taxes, net of federal benefit	(0.3)	0.3
Foreign tax rate differential	0.4	1.3	0.9
Change in valuation allowance	4.1	4.2	2.8
Gain on merger	0.1	(3.0)
Research and development expenses	(0.1)	1.1	2.9
Research and development tax credits	(0.3)	(1.1)	(0.3)
Employee stock options		0.5	0.2
Other	(0.2)	0.1	(0.1)
Income tax expense (benefit)	$ (0.3)	$ 0.1	$ (0.5)

Note 9 - Income Taxes (Details) - Summary of Deferred Tax Assets and Liabilities - USD ($) $ in Millions	Jun. 30, 2014	Jun. 30, 2013
Deferred tax assets:
Foreign net operating loss carryforwards	$ 18.2	$ 18.2
US federal and state loss carryforwards	2.8
Amortization	0.8	0.8
Depreciation	0.6	0.2
Accrued compensated-related costs	0.8	0.4
Other	4.3	3.7
Subtotal	27.5	23.3
Less Valuation Allowance	(26.4)	(21.4)
Total Net DTA	1.1	1.9
Unearned Income	(1.1)	(1.9)
Net deferred tax assets	0.0	0.0
Current net DTL	(0.9)	(1.5)
Noncurrent net DTA	$ 0.9	$ 1.5

Note 10 - Share-based Compensation (Details) - USD ($)

1 Months Ended

9 Months Ended

12 Months Ended

Aug. 31, 2014

Dec. 31, 2013

Mar. 31, 2014

Jun. 30, 2014

Jun. 30, 2013

Note 10 - Share-based Compensation (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares (in Shares)

432,975

Performance Shares [Member]

Note 10 - Share-based Compensation (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 0

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

432,975

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

$ 4.15

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

$ 1,000,000

Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period

6 years

MSU [Member] | Minimum [Member]

Note 10 - Share-based Compensation (Details) [Line Items]

Percentage of the Target Number of Units Granted Earned Based on Stock Performance

0.00%

MSU [Member] | Maximum [Member]

Note 10 - Share-based Compensation (Details) [Line Items]

Percentage of the Target Number of Units Granted Earned Based on Stock Performance

250.00%

MSU [Member]

Note 10 - Share-based Compensation (Details) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period (in Shares)

108,183

The 2007 Omnibus Equity and Incentive Plan [Member]

Note 10 - Share-based Compensation (Details) [Line Items]

Allocated Share-based Compensation Expense

$ 1,700,000

$ 2,600,000

Employee Service Share-based Compensation, Tax Benefit from Compensation Expense

$ 0

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in Shares)

^[1]

912,975

Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in Dollars per share)

^[1]

$ 3.95

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized

$ 3,500,000

Proceeds from Stock Options Exercised

Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value

$ 0

Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition

2 years

[1]	Includes performance-based options of 432,975, subject to specific performance conditions.

Note 10 - Share-based Compensation (Details) - Fair Value Assumptions - $ / shares	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Fair Value Assumptions [Abstract]
Weighted-average risk-free interest rate	1.50%	1.50%
Dividend yield	0.00%	0.00%
Expected weighted-average volatility	0.79%	0.79%
Expected weighted-average term of options (years)	5 years 335 days	6 years
Weighted-average fair value of options granted (in Dollars per share)	$ 2.47	$ 2.39

Note 10 - Share-based Compensation (Details) - Stock Option Activity
$ / shares in Units, $ in Millions

12 Months Ended

Jun. 30, 2014

USD ($)

$ / shares

Stock Option Activity [Abstract]

Granted (1) | shares

912,975

^[1]

Granted (1) | $ / shares

$ 3.95

^[1]

Forfeited or expired | shares

(108,135)

Forfeited or expired | $ / shares

$ 34.36

Balance at June 30, 2014 | shares

2,463,369

Balance at June 30, 2014 | $ / shares

$ 9.09

Balance at June 30, 2014

6 years 124 days

Balance at June 30, 2014 | $

$ 0

[1]	Includes performance-based options of 432,975, subject to specific performance conditions.

Note 10 - Share-based Compensation (Details) - Exercise Price Range Relating to Oustanding and Exercisable Options	12 Months Ended
	Jun. 30, 2014 $ / shares shares
Range One [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices Lower Limit	$ 2.56
Exercise Price Weighted Average	3.38
Exercise Prices Upper Limit	$ 4.05
Outstanding Number of Shares (in Shares) \| shares	490,000
Outstanding Weighted Average Remaining Contractual Life	9 years 80 days
Exercisable Weighted Average Exercise Price	$ 3.96
Exercisable Number of Shares (in Shares) \| shares	86,250
Range Two [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices Lower Limit	$ 4.07
Exercise Price Weighted Average	$ 4.07
Outstanding Number of Shares (in Shares) \| shares	931,590
Outstanding Weighted Average Remaining Contractual Life	8 years 135 days
Exercisable Weighted Average Exercise Price	$ 4.07
Exercisable Number of Shares (in Shares) \| shares	310,531
Range Three [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices Lower Limit	$ 4.13
Exercise Price Weighted Average	4.38
Exercise Prices Upper Limit	$ 6.65
Outstanding Number of Shares (in Shares) \| shares	628,675
Outstanding Weighted Average Remaining Contractual Life	3 years 178 days
Range Four [Member]
Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range [Line Items]
Exercise Prices Lower Limit	$ 11.22
Exercise Price Weighted Average	34.37
Exercise Prices Upper Limit	$ 93.36
Outstanding Number of Shares (in Shares) \| shares	413,104
Outstanding Weighted Average Remaining Contractual Life	2 years 251 days
Exercisable Weighted Average Exercise Price	$ 34.37
Exercisable Number of Shares (in Shares) \| shares	413,104
Exercise Price Weighted Average	$ 9.09
Outstanding Number of Shares (in Shares) \| shares	2,463,369
Outstanding Weighted Average Remaining Contractual Life	6 years 124 days
Exercisable Weighted Average Exercise Price	$ 19.51
Exercisable Number of Shares (in Shares) \| shares	809,885

Note 10 - Share-based Compensation (Details) - Summary of Restricted Stock Awards - Restricted Stock [Member]	12 Months Ended
	Jun. 30, 2014 $ / shares shares
Note 10 - Share-based Compensation (Details) - Summary of Restricted Stock Awards [Line Items]
Outstanding at June 30, 2013 \| shares	0
Outstanding at June 30, 2013 \| $ / shares	$ 0
Granted \| shares	54,000
Granted \| $ / shares	$ 4.10
Released \| shares	(45,250)
Released \| $ / shares	$ 4.13
Outstanding at June 30, 2014 \| shares	8,750
ShareBasedCompensationNonOptionOutstandingWeightedAverageGrantDateFairValue \| $ / shares	$ 3.93

Note 10 - Share-based Compensation (Details) - Summary of MSU Activity - Restricted Stock and Market Stock Units [Member]	12 Months Ended
	Jun. 30, 2014 $ / shares shares
Note 10 - Share-based Compensation (Details) - Summary of MSU Activity [Line Items]
Outstanding at June 30, 2013 \| shares	170,139
Outstanding at June 30, 2013 \| $ / shares	$ 4.07
Awarded \| shares	123,183
Awarded \| $ / shares	$ 3.86
Released \| shares	(17,400)
Released \| $ / shares	$ 4.05
Forfeited \| shares	(13,850)
Forfeited \| $ / shares	$ 4.02
Unvested at June 30, 2014 \| shares	262,072
Unvested at June 30, 2014 \| $ / shares	$ 3.98

Note 10 - Share-based Compensation (Details) - MSU Fair Value Assumptions - $ / shares	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
MSU [Member]
Note 10 - Share-based Compensation (Details) - MSU Fair Value Assumptions [Line Items]
Expected dividend yield	0.00%	0.00%
Expected stock price volatility	0.86%	0.00%
Risk-free interest rate	0.64%	0.00%
20-day trading average stock price on grant date (in Dollars per share)	$ 3.98	$ 0
Weighted-average per share grant date fair value (in Dollars per share)	$ 7.69	$ 0
Expected dividend yield	0.00%	0.00%
Risk-free interest rate	1.50%	1.50%

Note 11 - Retirement Benefits (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Non U.S. Employees [Member]
Note 11 - Retirement Benefits (Details) [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	9.00%
U.S. Employee [Member]
Note 11 - Retirement Benefits (Details) [Line Items]
Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay	4.00%
Defined Contribution Plan, Cost Recognized	$ 0.8	$ 1.1	$ 1.1

Note 12 - Net Loss per Share (Details) - Computation of Historical Basic and Diluted Net Income (Loss) Per Share - USD ($)
$ / shares in Units, $ in Millions

3 Months Ended

12 Months Ended

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Prior to Adjustments [Member]

Note 12 - Net Loss per Share (Details) - Computation of Historical Basic and Diluted Net Income (Loss) Per Share [Line Items]

Weighted-average shares outstanding

31,347,888

28,217,515

181,775,444

Adjusted Using Exchange Ratio [Member]

Note 12 - Net Loss per Share (Details) - Computation of Historical Basic and Diluted Net Income (Loss) Per Share [Line Items]

Weighted-average shares outstanding

22,713,566

Basic loss per share (in Dollars per share)

$ (0.35)

$ (0.32)

$ (0.85)

Diluted loss per share (in Dollars per share)

$ (0.35)

$ (0.32)

$ (0.85)

Net loss (in millions) (in Dollars)

$ (10.2)

$ 3.2

$ (0.1)

$ (3.9)

$ (6.5)

$ 0.2

$ 4.6

$ (7.2)

$ (11.0)

$ (8.9)

$ (19.2)

Shares used to compute diluted earnings per share

31,347,888

28,217,515

22,713,566

Basic loss per share (in Dollars per share)

^[1]

$ (0.29)

$ 0.09

$ 0.00

$ (0.14)

$ (0.23)

$ 0.01

$ 0.16

$ (0.32)

Diluted loss per share (in Dollars per share)

^[1]

$ (0.29)

$ 0.09

$ 0.00

$ (0.14)

$ (0.23)

$ 0.01

$ 0.16

$ (0.32)

Number of antidilutive stock options excluded from computation

2,725,441

1,828,668

[1]	Due to the use of the weighted average shares outstanding for each quarter for computing earnings per share, the sum of the quarterly per share amounts maynot equal the per share amount for the year.

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

Consolidated Quarterly Financial Information [Abstract]

Note 13 - Research and Development Credit (Details) - USD ($)	12 Months Ended
	Jun. 30, 2014	Jun. 30, 2013
Research and Development [Abstract]
Research and Development Credit	$ 0	$ 4,400,000

Note 14 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Mar. 31, 2011	Jun. 30, 2014	Jun. 30, 2013
United States, Europe, Japan and Other Countries [Member] \| GSK
Note 14 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Royalty Payment Percentage		7.00%
Australia, New Zealand, South Africa and Indonesia \| GSK
Note 14 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Royalty Payment Percentage		10.00%
Japan [Member] \| Daiichi Sankyo
Note 14 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Royalty Payment Percentage		4.00%
BARDA
Note 14 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) [Line Items]
Maximum Revenue from Contract	$ 231.2
Contract Term	5 years
Contract Receivable		$ 17.8
Contracts Receivable, Claims and Uncertain Amounts	$ 3.7
Contract Receivable		$ 17.8	$ 10.9

Note 14 - Licenses, Royalty Collaborative and Contractual Arrangements (Details) - Components of Revenues from Royalties, Collaborative and Contractual Agreements - USD ($) $ in Millions	3 Months Ended								12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Jun. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2012	Jun. 30, 2014	Jun. 30, 2013	Jun. 30, 2012
Relenza [Member]
Segment Reporting Information [Line Items]
Royalty revenue									$ 10.6	$ 2.6	$ 4.4
Inavir [Member]
Segment Reporting Information [Line Items]
Royalty revenue									4.5	4.2	4.5
Royalty revenue									15.1	9.6	8.8
Commercial milestone – Inavir®										2.8
Revenue from services									53.6	24.0	11.5
Total revenue	$ 8.5	$ 29.5	$ 18.5	$ 12.3	$ 9.3	$ 12.5	$ 10.4	$ 1.4	$ 68.7	$ 33.6	$ 20.4

Note 15 - Restructuring Charges (Details) - USD ($) $ in Millions	12 Months Ended
	Jun. 30, 2015	Jun. 30, 2014	Jun. 30, 2013
Cost of Sales [Member] \| Employee Severance [Member]
Note 15 - Restructuring Charges (Details) [Line Items]
Restructuring Charges		$ 0.9
Research and Development Expense [Member] \| Employee Severance [Member]
Note 15 - Restructuring Charges (Details) [Line Items]
Restructuring Charges		1.0
Selling, General and Administrative Expenses [Member] \| Employee Severance [Member]
Note 15 - Restructuring Charges (Details) [Line Items]
Restructuring Charges		0.2
Scenario, Forecast [Member] \| Employee Severance [Member]
Note 15 - Restructuring Charges (Details) [Line Items]
Restructuring Charges	$ 2.0
Employee Severance [Member]
Note 15 - Restructuring Charges (Details) [Line Items]
Restructuring Charges		2.1
Restructuring Reserve		2.0
Nabi [Member]
Note 15 - Restructuring Charges (Details) [Line Items]
Severance Obligations Accrued		1.2	$ 1.0
Restructuring Charges		2.1
Restructuring Reserve		2.0
Severance Obligations Accrued		$ 1.2	$ 3.0

Note 15 - Restructuring Charges (Details) - Reconciliation of the Beginning and Ending Balances of the Restructuring Liability: $ in Millions	12 Months Ended
	Jun. 30, 2014 USD ($)
Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring Charges	$ 2.1
Payments for Restructuring	(0.1)
Restructuring Liability, Ending Balance	2.0
Restructuring Charges	2.1
Payments for Restructuring	(0.1)
Restructuring Liability, Ending Balance	$ 2.0

Note 16 - Quarterly Financial Information (Unaudited) (Details) - Consolidated Quarterly Financial Information - USD ($)
$ / shares in Units, $ in Millions

3 Months Ended

12 Months Ended

Jun. 30, 2014

Mar. 31, 2014

Dec. 31, 2013

Sep. 30, 2013

Jun. 30, 2013

Mar. 31, 2013

Dec. 31, 2012

Sep. 30, 2012

Jun. 30, 2014

Jun. 30, 2013

Jun. 30, 2012

Revenues

$ 8.5

$ 29.5

$ 18.5

$ 12.3

$ 9.3

$ 12.5

$ 10.4

$ 1.4

$ 68.7

$ 33.6

$ 20.4

Operating expenses

19.0

19.3

11.4

10.7

7.7

4.1

7.1

1.5

Net (loss) income

$ (10.2)

$ 3.2

$ (0.1)

$ (3.9)

$ (6.5)

$ 0.2

$ 4.6

$ (7.2)

$ (11.0)

$ (8.9)

$ (19.2)

Net (loss) income per share (1):

Basic (in Dollars per share)

^[1]

$ (0.29)

$ 0.09

$ 0.00

$ (0.14)

$ (0.23)

$ 0.01

$ 0.16

$ (0.32)

Diluted (in Dollars per share)

^[1]

$ (0.29)

$ 0.09

$ 0.00

$ (0.14)

$ (0.23)

$ 0.01

$ 0.16

$ (0.32)

[1]	Due to the use of the weighted average shares outstanding for each quarter for computing earnings per share, the sum of the quarterly per share amounts maynot equal the per share amount for the year.

The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.